Kane Biotech Expands U.S. Commercial Reach

Announces new distribution deals for antimicrobial wound care products

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Kane Biotech Inc., a Canadian biotech company, has signed non-exclusive distribution and sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical in Texas and Life Biologics in New Jersey. This expansion into targeted U.S. sales channels and geographic markets is a key priority for the company as it works to commercialize its FDA-cleared and Health Canada-approved wound care products.

Why it matters

Biofilms are a major contributor to antibiotic resistance in wounds, leading to serious clinical outcomes and significant costs. Kane Biotech's revyve® products aim to disrupt biofilms and transform wound healing. Expanding distribution in the U.S. market is crucial for the company to drive near-term commercialization and growth.

The details

The new distribution agreements will allow Kane Biotech to reach targeted U.S. markets through Life Biologics' national distribution in advanced wound care and Patient Care Medical's focus on in-hospital and mobile wound care facilities in Louisiana, Mississippi, and the Gulf Coast region. The company says preparations are underway for initial product shipments in the near term.

  • Kane Biotech announced the new distribution agreements on February 19, 2026.

The players

Kane Biotech Inc.

A Canadian biotech company that is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes.

Patient Care Medical

A Texas-based distributor that will sell Kane Biotech's revyve® products in Louisiana, Mississippi, and the Gulf Coast region, specializing in in-hospital and mobile wound care facilities.

Life Biologics

A New Jersey-based distributor that will sell Kane Biotech's revyve® products nationally in the advanced wound care market.

Dr. Robert Huizinga

The Interim CEO of Kane Biotech.

Ray Dupuis

The Chief Financial Officer of Kane Biotech.

Got photos? Submit your photos here. ›

What they’re saying

“Expanding our U.S. distribution network remains a key priority for the Company. These agreements enhance our access to selected U.S. markets and support our near-term commercialization objectives.”

— Dr. Robert Huizinga, Interim CEO, Kane Biotech Inc. (Kane Biotech Press Release)

What’s next

Kane Biotech says preparations are underway for initial shipments of its revyve® products to the new U.S. distributors in the near term.

The takeaway

Kane Biotech's expansion into the U.S. market through these new distribution agreements is a critical step in the company's efforts to commercialize its innovative antimicrobial wound care products and address the growing challenge of antibiotic resistance in wound care.